Top Suppliers:I want be here



256376-24-6

256376-24-6 structure
256376-24-6 structure
  • Name: BAY 41-2272
  • Chemical Name: 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine
  • CAS Number: 256376-24-6
  • Molecular Formula: C20H17FN6
  • Molecular Weight: 360.388
  • Catalog: Signaling Pathways GPCR/G Protein Guanylate Cyclase
  • Create Date: 2017-12-05 13:33:03
  • Modify Date: 2024-01-02 16:08:58
  • BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.Target: guanylate cyclaseBAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2]

Name 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine
Synonyms 5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine
5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
bay-41-2272
4-pyrimidinamine, 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-
unii-34a162j6wb
BAY 41-2272
Description BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.Target: guanylate cyclaseBAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2]
Related Catalog
References

[1]. Tuttle TR, et al. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Lett. 2016 Jan 28;370(2):279-85.

[2]. Boerrigter G, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003 Feb 11;107(5):686-9.

Density 1.5±0.1 g/cm3
Boiling Point 496.1±45.0 °C at 760 mmHg
Molecular Formula C20H17FN6
Molecular Weight 360.388
Flash Point 253.8±28.7 °C
Exact Mass 360.149872
PSA 83.24000
LogP 1.99
Vapour Pressure 0.0±1.3 mmHg at 25°C
Index of Refraction 1.767
Storage condition -20℃